Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 537

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 537
---
     |   $17,120 |

Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 15 years. Successor’s amortization expense was $714 and $184 for the year ended December 31, 2024 and for the period from September 28, 2023 to December 31, 2023, respectively. There was no amortization expense for the period from January 1, 2023 to September 27, 2023. Estimated amortization expense for the years ending December 31, 2025 through 2029 is $713 per year. The Company had no impairment of goodwill or intangible assets.

F-46

TABLE OF CONTENTS

Other long-term assets consist of the following: Other long-term assets as of December 31, 2024, are comprised of finished products (berdazimer gel, 10.3%). These finished products, while not currently available for commercial sale due to the different labeling utilized, the Company expects to use these units in the future as part of a patient assistance program. These items will be expensed when distributed. Accrued expenses consisted of the following:

|                                          |     | December 31, |     |           |
|                                          |     |         2024 |     |      2023 |
|                                          |     |    Successor |     | Successor |
| Compensation                             |     |       $1,095 |     |    $1,110 |
| Drug product manufacturing subcontractor |     |          353 |     |         — |
| Other                                    |     |          593 |     |       300 |
| Total accrued expenses                   |     |       $2,041 |     |    $1,410 |

Note 8: Leases On January 18, 2021, the Company entered into a lease with an initial term expiring in 2032, as amended for 19,265 rentable square feet, located in Durham, North Carolina. This lease dated as of January 18, 2021, as amended (the “TBC Lease”), is by and between the Company and Copper II 2020, LLC (the “TBC Landlord”), pursuant to which the Company is leasing space serving as its corporate headquarters and primary API manufacturing site (the “Premises”) located within the Triangle Business Center. The lease executed on January 18, 2021, as amended, was